Compare Stocks: EVGN, CARM, INAB, and HIND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.00	$0.00	$0.00 ▼ $0.29	$21K	-9.6	56,454 shs	814 shs
EVGN Evogene	$0.40 -2.9%	$0.52	$0.35 ▼ $1.49	$3.58M	1.44	3.81 million shs	88,142 shs
HIND Vyome	$2.05 +0.5%	$2.12	$1.75 ▼ $6.56	$14.32M	1.53	21,917 shs	8,004 shs
INAB IN8bio	$1.35 -3.6%	$1.14	$0.88 ▼ $2.73	$13.80M	0.3	51,280 shs	20,918 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	0.00%	-28.57%	-28.57%	-90.91%	-99.81%
EVGN Evogene	-3.09%	+3.40%	-23.67%	-17.88%	-69.11%
HIND Vyome	-0.97%	+5.70%	-8.11%	-8.52%	-67.15%
INAB IN8bio	+0.72%	+2.94%	+16.67%	0.00%	-43.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.00	$0.00	$0.00 ▼ $0.29	$21K	-9.6	56,454 shs	814 shs
EVGN Evogene	$0.40 -2.9%	$0.52	$0.35 ▼ $1.49	$3.58M	1.44	3.81 million shs	88,142 shs
HIND Vyome	$2.05 +0.5%	$2.12	$1.75 ▼ $6.56	$14.32M	1.53	21,917 shs	8,004 shs
INAB IN8bio	$1.35 -3.6%	$1.14	$0.88 ▼ $2.73	$13.80M	0.3	51,280 shs	20,918 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	0.00%	-28.57%	-28.57%	-90.91%	-99.81%
EVGN Evogene	-3.09%	+3.40%	-23.67%	-17.88%	-69.11%
HIND Vyome	-0.97%	+5.70%	-8.11%	-8.52%	-67.15%
INAB IN8bio	+0.72%	+2.94%	+16.67%	0.00%	-43.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	0.00	N/A	N/A	N/A
EVGN Evogene	1.00	Sell	N/A	N/A
HIND Vyome	2.25	Hold	$3.50	70.73% Upside
INAB IN8bio	2.00	Hold	$4.00	196.30% Upside

Current Analyst Ratings Breakdown

Latest EVGN, CARM, INAB, and HIND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	EVGN Evogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	HIND Vyome	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.50
9/3/2026	HIND Vyome	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.50
7/29/2026	HIND Vyome	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	INAB IN8bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	EVGN Evogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$10.77M	0.00	N/A	N/A	($0.67) per share	0.00
EVGN Evogene	$3.85M	0.90	N/A	N/A	$1.37 per share	0.29
HIND Vyome	$320K	44.97	N/A	N/A	$0.67 per share	3.06
INAB IN8bio	N/A	N/A	N/A	N/A	$2.82 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	$0.73	0.00	N/A	N/A	-254.28%	N/A	-192.17%	11/5/2026 (Estimated)
EVGN Evogene	-$8.48M	-$0.91	N/A	N/A	N/A	-694.18%	-156.53%	-86.80%	11/19/2026 (Estimated)
HIND Vyome	-$10.26M	-$3.37	N/A	N/A	N/A	-3,024.84%	-197.33%	-138.14%	N/A
INAB IN8bio	-$19.44M	-$1.62	N/A	N/A	N/A	N/A	-91.18%	-76.93%	11/5/2026 (Estimated)

Latest EVGN, CARM, INAB, and HIND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	N/A	CARM Carisma Therapeutics	-$0.1237	N/A	N/A	N/A	$4.66 million	N/A
11/5/2026	Q3 2026	INAB IN8bio	-$0.3367	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	HIND Vyome	N/A	-$0.10	N/A	-$0.10	N/A	$0.27 million
8/6/2026	Q2 2026	INAB IN8bio	-$0.3437	-$0.25	+$0.0937	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
EVGN Evogene	N/A	N/A	N/A	N/A	N/A
HIND Vyome	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	0.48	0.48
EVGN Evogene	N/A	3.57	3.54
HIND Vyome	N/A	4.37	4.37
INAB IN8bio	N/A	8.21	8.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
EVGN Evogene	10.40%
HIND Vyome	22.06%
INAB IN8bio	92.05%

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	6.90%
EVGN Evogene	7.40%
HIND Vyome	33.00%
INAB IN8bio	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.85 million	38.91 million	No Data
EVGN Evogene	52	8.72 million	8.07 million	No Data
HIND Vyome	18	7.02 million	4.70 million	N/A
INAB IN8bio	18	9.86 million	8.43 million	Not Optionable

EVGN, CARM, INAB, and HIND Headlines

Recent News About These Companies

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 6 at 4:00 PM | globenewswire.com

IN8bio consensus price target raised 12% to $7.14

October 3, 2026 | msn.com

IN8bio Highlights Glioblastoma Survival Data, Eyes Autoimmune T-Cell Engager Milestone

September 28, 2026 | americanbankingnews.com

IN8bio to Present at Sidoti Small-Cap Virtual Conference

September 22, 2026 | globenewswire.com

In8bio stock trades on small-cap valuation as investors eye latest clinical updates

September 22, 2026 | ad-hoc-news.deA

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026 | globenewswire.com

IN8bio, Inc: IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

September 9, 2026 | finanznachrichten.de

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

September 9, 2026 | globenewswire.com

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 6, 2026 | finance.yahoo.com

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

July 9, 2026 | globenewswire.com

Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), IN8bio (INAB)

July 8, 2026 | theglobeandmail.com

IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

June 4, 2026 | zacks.com

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T ...

June 3, 2026 | caledonianrecord.comC

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies

June 3, 2026 | globenewswire.com

In8bio (INAB) Stock Forecast & Price Target

June 2, 2026 | investing.com

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

June 1, 2026 | globenewswire.com

IN8bio launches new JonesTrading at-the-market program

June 1, 2026 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and IN8bio (INAB)

May 23, 2026 | theglobeandmail.com

IN8bio, Inc: IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 8, 2026 | finanznachrichten.de

IN8bio Reports Q1 2026 Results and Shareholder Votes

May 7, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EVGN, CARM, INAB, and HIND Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.0005 0.00 (0.00%)

As of 12:25 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evogene NASDAQ:EVGN

$0.40 -0.01 (-2.95%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 +0.01 (+1.38%)

As of 07:55 PM Eastern

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Vyome NASDAQ:HIND

$2.05 +0.01 (+0.49%)

Closing price 03:58 PM Eastern

Extended Trading

$2.02 -0.03 (-1.71%)

As of 07:30 PM Eastern

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

IN8bio NASDAQ:INAB

$1.35 -0.05 (-3.57%)

Closing price 03:54 PM Eastern

Extended Trading

$1.32 -0.03 (-2.00%)

As of 07:50 PM Eastern

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVGN, CARM, INAB, and HIND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVGN, CARM, INAB, and HIND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVGN, CARM, INAB, and HIND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EVGN, CARM, INAB, and HIND Company Descriptions

Carisma Therapeutics NASDAQ:CARM

Evogene NASDAQ:EVGN

Vyome NASDAQ:HIND

IN8bio NASDAQ:INAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVGN, CARM, INAB, and HIND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVGN, CARM, INAB, and HIND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVGN, CARM, INAB, and HIND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EVGN, CARM, INAB, and HIND Company Descriptions

Carisma Therapeutics NASDAQ:CARM

Evogene NASDAQ:EVGN

Vyome NASDAQ:HIND

IN8bio NASDAQ:INAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools